Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPPER PET in NET
NCT06455358Phase 2Recruiting
- Sponsor
- University Hospital Basel
- Start
- Feb 2025
- Primary completion
- Jun 2028
- Modality
- Positron Emission Tomography Imaging
- Countries
- 1
01
Overview
A Phase 2 trial of 61Cu-NODAGA-LM3 in neuroendocrine tumors (NETs), sponsored by University Hospital Basel. Started Feb 2025; status: recruiting.
02
Drugs
61Cu-NODAGA-LM3
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT06455358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455358.